10-Q: Ascend Wellness Holdings Reports Modest Revenue Growth, Margin Improvement

Ascend Wellness Holdings, Inc. (AWH) reported a 4% increase in revenue for the third quarter of 2026 compared to the prior year, driven by acquisitions and new store openings, alongside improved gross margins, though net losses persist.

Summary

• Ascend Wellness Holdings (AWH) reported Q3 2026 revenue of $130.0 million, a 4% increase year-over-year, driven by new acquisitions and store openings, partially offset by declines in legacy business due to competition and pricing pressure.
• Gross profit increased by 22% to $53.1 million, with gross margin improving to 40.8% from 35.0% in the prior year's quarter, benefiting from higher volumes through company-owned and partner stores and a focus on higher-margin products.
• General and administrative expenses rose by 8% to $48.6 million, primarily due to increased compensation and depreciation, while interest expense surged by 75% to $22.0 million, largely due to higher finance lease interest.
• The company reported a net loss of $28.0 million for the quarter, an increase from $25.8 million in Q3 2025, and a net loss of $67.3 million for the nine months ended September 30, 2026.
• Cash and cash equivalents decreased to $63.6 million as of September 30, 2026, from $85.7 million at the end of 2025, with net cash provided by operating activities at $8.5 million for the nine months ended September 30, 2026.
• The company is evaluating the impact of the April 2026 DOJ order to reschedule cannabis to Schedule III, which could provide relief from IRC Section 280E for medical cannabis activities, but the details and timing remain uncertain.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While revenue saw a modest increase and gross margins improved, the company continues to report significant net losses and a substantial accumulated deficit. The potential benefits from cannabis rescheduling are noted but remain uncertain.

Positives

• Revenue increased by 4% to $130.0 million in Q3 2026 compared to Q3 2025.
• Gross profit increased by 22% to $53.1 million, with gross margin improving to 40.8% from 35.0%.
• The company recognized relief from IRC Section 280E for its qualifying medical cannabis activities in the current period.
• Cash and cash equivalents of $63.6 million as of September 30, 2026, combined with anticipated operating cash flows, are believed by management to be adequate for the next twelve months.
• Acquisitions and consolidated partnership activity contributed $18.1 million in incremental revenue during the quarter.
• Lower inventory write-downs of $0.2 million in Q3 2026 compared to $7.0 million in Q3 2025.

Negatives

• Net loss for the quarter was $27.95 million, an increase from $25.83 million in the prior year.
• Accumulated deficit was $585.8 million as of September 30, 2026.
• Interest expense increased by 75% to $21.98 million in Q3 2026 compared to Q3 2025, largely due to finance leases.
• General and administrative expenses increased by 8% to $48.59 million in Q3 2026.
• Net cash used in investing activities was $26.4 million for the nine months ended September 30, 2026.
• The company faces ongoing price compression and increased competition in several markets.

Risks

• The illegality of cannabis under federal law and the uncertainty surrounding federal cannabis rescheduling, including the administrative hearing concerning broader rescheduling.
• Risks related to compliance with complex and evolving state and local cannabis regulations, including licensing, renewals, and enforcement.
• The effect of unfavorable tax treatment for cannabis businesses, particularly the ongoing uncertainty regarding the application of IRC Section 280E to adult-use operations and the details of federal rescheduling guidance.
• Intense competition in the industry and the maturation of the cannabis market leading to adverse changes in wholesale and retail prices.
• Challenging or volatile global economic, political, or financial conditions, including inflation, interest rates, supply chain disruptions, and reduced consumer spending.
• Cybersecurity risks, data privacy concerns, and reliance on third-party service providers.
• Unknown health impacts associated with the use of cannabis and cannabis derivative products.
• Litigation, regulatory investigations, and enforcement actions, including the ongoing State of Ohio complaint and EEOC lawsuit.

Future Outlook

Management believes current cash and cash equivalents, combined with anticipated cash flows from operations, are adequate to support operations for the next twelve months. The company may access capital markets for additional funding through debt and/or equity financings if needed. Future growth is expected from opening new dispensaries, expanding cultivation facilities, and increasing consumer demand. The company anticipates net capital expenditures of approximately $20,000 during 2026.

Management Comments

• Management believes that cash and cash equivalents, combined with anticipated cash flows from operating activities, is more than adequate to support operations for the next twelve months.
• Management may continue to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs, as may be required.
• The Company denies the claims in the State of Ohio complaint and plans to vigorously contest the case.
• The Company disputes the allegations in the EEOC complaint and intends to defend the matter vigorously.

Industry Context

StockSavvy.ai notes that Ascend Wellness Holdings operates in a highly regulated and evolving cannabis industry. The recent DOJ order to reschedule certain cannabis products to Schedule III presents both opportunities for tax relief (from IRC Section 280E) and significant uncertainty, particularly for companies with mixed medical and adult-use operations. The company's focus on limited license markets and expansion through acquisitions aligns with industry trends, but competitive pressures and pricing challenges are evident.

Comparison to Industry Standards

• Ascend Wellness Holdings' gross margin of 40.8% for Q3 2026 is an improvement from 35.0% in the prior year, indicating better operational efficiency or pricing power in certain segments. This margin is competitive within the multi-state operator (MSO) landscape, though specific comparisons depend on the product mix and market focus of peers like Curaleaf, Trulieve, and Green Thumb Industries.
• The company's net loss of $28.0 million for the quarter and an accumulated deficit of $585.8 million highlight the ongoing profitability challenges faced by many MSOs, which are often burdened by high debt levels and regulatory complexities.
• The significant increase in interest expense (75% year-over-year) is a common theme among highly leveraged cannabis companies, impacting overall profitability. This contrasts with companies that have managed to reduce debt or secure more favorable financing terms.
• The potential tax benefits from the rescheduling of cannabis to Schedule III could significantly alter the financial landscape for MSOs. Companies that can effectively navigate the allocation of expenses between medical (potentially 280E exempt) and adult-use (still subject to 280E) operations will be better positioned than those that cannot, a challenge faced by AWH and its peers.
• The company's strategy of expanding through acquisitions and consolidating partnerships is a standard approach in the MSO sector to gain market share and operational scale, as seen with competitors like Verano Holdings and Cresco Labs.

Corporate Governance

Legal Proceedings

• State of Ohio complaint alleging anticompetitive collusion among MSOs to exclude single state operators.
• EEOC lawsuit alleging violation of Title VII of the Civil Rights Act of 1964 due to a sexually hostile work environment at a dispensary.
• Green Thumb Industries arbitration matter resolved via a $17,000 settlement payment.

Related Party Transactions

• No significant related party transactions during the nine months ended September 30, 2026, other than those disclosed in Note 12, Stockholders Equity (Deficit).

Stakeholder Impact

• Shareholders: Continued net losses and accumulated deficit may impact investor confidence, though revenue growth and margin improvement are positive signs. Potential for future capital raises could dilute existing shareholders.
• Employees: Increased compensation expense noted, supporting expansion. The EEOC lawsuit highlights potential risks related to workplace environment.
• Creditors: Significant debt levels and interest expenses require careful management. The company's liquidity is deemed adequate for the next twelve months, but future capital needs are acknowledged.
• Suppliers: Standard commercial relationships are in place; no specific impacts mentioned.
• Customers: Continued focus on providing safe, reliable, and high-quality products and education.

Next Steps

• Continue to focus on optimizing operations and evaluating expansion opportunities.
• Monitor and adapt to evolving federal and state cannabis regulations, including the impact of the April 2026 DOJ order.
• Pursue regulatory approval for pending acquisitions.
• Manage debt obligations and explore potential future financing arrangements.
• Continue to enhance product offerings, such as the revamped Ozone-branded products.
• Address ongoing legal proceedings, including the State of Ohio complaint and EEOC lawsuit.

Key Dates

Recommendation

Ascend Wellness Holdings shows signs of operational improvement with increased revenue and better gross margins. However, the persistent net losses, substantial accumulated deficit, and high interest expenses, coupled with the significant uncertainties surrounding cannabis regulation and taxation (especially IRC Section 280E), warrant a cautious approach. While the potential benefits of federal rescheduling are a positive development, their realization is uncertain. The company's ability to manage its debt and navigate regulatory complexities will be key. Therefore, a 'hold' recommendation is appropriate, pending clearer visibility on profitability and regulatory clarity.

Keywords

cannabis, multi-state operator, retail dispensaries, wholesale, acquisitions, revenue, net loss, taxation